MYELOFLUDATEP: Exploratory study evaluating the value of 18F-Fludarabine PET for the initial or relapsed assessment and therapeutic evaluation of patients with symptomatic multiple myeloma.

2024-515219-23-00 Protocol RC18_0055 Human pharmacology (Phase I) - Other Ongoing, recruiting

Start 8 Nov 2024 · Status Ongoing, recruiting · 1 EU/EEA countries · 5 sites · Protocol RC18_0055

Overview

Sponsor-declared trial summary

Phase Human pharmacology (Phase I) - Other
Status Ongoing, recruiting
Participants planned 35
Countries 1
Sites 5

multiple myeloma

Key facts

Sponsor
Centre Hospitalier Universitaire De Nantes
Participant type
Patients
Age range
18-64 years, 65+ years
Gender
Male and Female
Therapeutic area
Analytical, Diagnostic and Therapeutic Techniques and Equipment [E] - Diagnosis [E01]
Trial duration
8 Nov 2024 → ongoing
Decision date (initial)
2024-11-08
Transition trial
Yes
Low-intervention
No
Rare-disease indication
No
Vulnerable population
No

External identifiers

EU CT number
2024-515219-23-00
EudraCT number
2018-002723-42

Trial design

CTIS Part I — objectives, methods, condition coding

Conditions and MedDRA coding

multiple myeloma

Sponsors and contacts

Sponsor organisations, regulatory contacts, third parties

Centre Hospitalier Universitaire De Nantes

Sponsor organisation
Centre Hospitalier Universitaire De Nantes
Address
5 Allee De L Ile Gloriette, Cs 69301 Cs 69301
City
Nantes Cedex 1
Postcode
44093
Country
France

Scientific contact point

Organisation
Centre Hospitalier Universitaire De Nantes
Contact name
Caroline BODET-MILIN

Public contact point

Organisation
Centre Hospitalier Universitaire De Nantes
Contact name
Caroline BODET-MILIN

Locations

1 EU/EEA country · 5 investigational sites

By country

CountryMS statusPlanned subjectsSites
France Ongoing, recruiting 35 5
Rest of world 0

Investigational sites

France

5 sites · Ongoing, recruiting
Centre Hospitalier Universitaire De Caen Normandie
hematology, Avenue De La Cote De Nacre, Cs 30001, Caen Cedex 9
Centre Hospitalier Regional D'Angers
hematology, 4 Rue Larrey, 49100, Angers
Centre Hospitalier Regional Universitaire De Tours
nuclear medecine, 2 Boulevard Tonnelle, 37000, Tours
Centre Hospitalier Regional Et Universitaire De Brest
nuclear medecine, 2 Avenue Marechal Foch, 29200, Brest
Centre Hospitalier Universitaire De Nantes
nuclear medecine, 5 Allee De L Ile Gloriette, Cs 69301, Nantes Cedex 1

Country notifications

Trial-start, recruitment-start, end and early-termination notifications submitted per Member State

Country Trial startTrial end Recruitment startRecruitment end Early termination
France 2024-11-08 2024-11-08

Application history

2 submissions — initial application plus substantial / non-substantial modifications

#TypeCodeSubmittedReference MSConclusionDecision date
1 INITIAL IN 2024-09-30 France Acceptable
2024-11-08
2024-11-08
2 SUBSTANTIAL MODIFICATION SM-3 2025-07-30 France Acceptable 2025-08-08